Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
IN

NASDAQ · INDV

Indivior PLC

Healthcare · Drug Manufacturers - Specialty & Generic

$35.37

Up+$0.12 (+0.34%)

Updated Nov 2, 2026, 3:41 AM

SID Score

5.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.47B
P/E ratio
26.96
Dividend yield
0.00%
52-week range
$27.68 – $42.81
Volume
4.61M
Avg. volume
2.19M

Price performance · INDV

INDV price history

1M range · 0 trading sessions · Daily adjusted prices

INDV does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest INDV news

The latest Smart Investors Daily articles mentioning INDV.

Stock researchCompany · Overview

INDV research

Overview

Company profile and research snapshot.

Company profile

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$38.00
Implied upside
—
Analysts
—
INDV recent ratings
DateFirmRatingTarget
Oct 28, 2026BarclaysOverweight—
Aug 5, 2026BarclaysOverweight—
Jun 18, 2026BarclaysOverweight—
Jan 12, 2026HC Wainwright & Co.Buy—
Oct 31, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 30, 2026

Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative

Indivior Pharmaceuticals (INDV) moved back into focus after reporting record third quarter earnings and reaffirming its 2026 revenue outlook. This gave investors fresh numbers to weigh alongside an approved merger with Supernus Pharmaceuticals. Over the past year Indivior Pharmaceuticals has combined a 56.53% total shareholder return with a share price near US$35.37 that has eased 11.60% over the last 90 days, suggesting long term holders have been rewarded while shorter term momentum has...

Yahoo · Oct 30, 2026

Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter

Indivior Pharmaceuticals (NasdaqGS: INDV) reported record third quarter results, highlighting its strongest Q3 performance to date. Shareholders approved a merger with Supernus Pharmaceuticals that will see the combined business operate under the Supernus brand. The transaction is expected to close in the near term, with Indivior preparing for new leadership and integration planning. Record Q3 results and the Supernus merger reshape Indivior's future, but investors should weigh more than...

Yahoo · Oct 29, 2026

Indivior Reports Third Quarter 2026 Financial Results

Q3’26 Total Net Revenue of $356 Million, Up 13% YoYRecord Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of $161 Million in Q3'26Record Quarterly Adjusted EBITDA of $211 Million in Q3'26, Up 76% YoYNet Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59%, Up 2,100 Basis Points YoYOn Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOB

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By